Results 191 to 200 of about 337,814 (260)

Investigation of the In Vitro and In Vivo Metabolism and μ‐Opioid Receptor Affinity of the Nitazene N‐Pyrrolidino Fluetonitazene

Drug Testing and Analysis, EarlyView.
Eight metabolites for N‐pyrrolidino fluetonitazene were identified in vitro, three of which (M2, M6 and M8) were present in an authentic urine sample. M2 was the most abundant in vivo metabolite and is a common marker metabolite of nitazepyne‐type substances.
Severin Zemp, Gaia Alluisetti, Wolfgang Weinmann, Bettina Schrag, Frank Sporkert, Maurine Leclerc, Katharina Elisabeth Grafinger   +6 more
wiley   +1 more source

Electrochemical Stripping Analysis at Paper-Based (Bio)Sensors: Current State-of-the-Art and Prospects. [PDF]

Sensors (Basel)
Kokkinos C, Economou A.
europepmc   +1 more source

In Vitro Metabolism of Δ8‐, Δ9‐, and Δ10‐THC in Human Hepatocytes: Distinct Δ10‐THC Biotransformation and Implications for Drug Testing

Drug Testing and Analysis, EarlyView.
Δ8‐THC and Δ9‐THC showed comparable metabolic profiles. In contrast, Δ10‐THC underwent extensive glucuronidation and hydroxylation, with only minor formation of a carboxy metabolite, indicating a markedly different metabolic pathway. These differences may increase the risk of misidentification and misinterpretation in cannabis drug testing.
Robert Kronstrand, Henrik Green, Markus Loh, Fabian Rüttimann, Manuela Carla Monti   +4 more
wiley   +1 more source

Preparation of K₂SbPO₆-Loaded Porous Geopolymer Particles for Efficient Sr(II) Removal: Adsorption Performance and Mechanism. [PDF]

Materials (Basel)
Cheng C, Fang W, Ouyang G, Wang J.
europepmc   +1 more source

Enhanced Contribution of Biexciton‐Mediated Decay Kinetics in Perovskite Nanocrystals Via Sequential Ultrafast Excitation

ENERGY &ENVIRONMENTAL MATERIALS, EarlyView.
Sequential ultrafast excitation is shown to increase the relative kinetic weighting of biexciton‐mediated decay in CsPbBr3 nanocrystals without increasing the total excitation fluence. By temporally structuring excitation within the exciton lifetime, the early‐time fast decay contribution becomes more pronounced while the fitted fast decay constants ...
Lijie Wang, Renqian Zhou, Malte Oppermann, Xi Zhang, Jianxin Wang, Jun Yin, Osman M. Bakr, Majed Chergui, Omar F. Mohammed   +8 more
wiley   +1 more source

Machine learning‐based prediction of elevated N terminal pro brain natriuretic peptide among US general population

ESC Heart Failure, Volume 12, Issue 2, Page 859-868, April 2025.
Abstract Aims Natriuretic peptide‐based pre‐heart failure screening has been proposed in recent guidelines. However, an effective strategy to identify screening targets from the general population, more than half of which are at risk for heart failure or pre‐heart failure, has not been well established.
Yuichiro Mori, Shingo Fukuma, Kyohei Yamaji, Atsushi Mizuno, Naoki Kondo, Kosuke Inoue   +5 more
wiley   +1 more source

ESTREL-Fatigue-association of levodopa with post-stroke fatigue. [PDF]

Eur Stroke J
Boos L, Kaufmann JE, Sauter MI, Lyrer P, Zietz A, Trüssel S, Engelter SV, Luft AR, Polymeris A, Altersberger VL, Wiesner K, Held JPO, Rottenberger Y, Schwarz A, Medlin F, Accolla EA, Foucras S, Kägi G, De Marchis GM, Politz S, Greulich M, Tarnutzer AA, Sturzenegger R, Katan M, Fischer U, Nedeltchev K, Schär J, Deglon KVDK, Rapin PA, Salerno A, Seiffge D, Auer E, Lippert J, Bonati LH, Schuster-Amft C, Gäumann S, Chabwine JN, Humm AM, Möller JC, Schweinfurther R, Bujan B, Jedrysiak P, Sandor PS, Gonzenbach R, Veit M, Lutz D, Lienert C, Peters N, Strambo D, Müri RM, Schädelin S, Hemkens LG, Ford GA, Kuppuswamy A, Lerdal A, Simpson DB, English C, Blackwell S, Gensicke H, Traenka C, Engelter ST.   +60 more
europepmc   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Self-Referenced and Wide-Range Tunable Microwave Frequency Measurement Using Period-One Oscillation and Spectral Gating. [PDF]

Sensors (Basel)
Yang Z, Liu Z, Dong W.
europepmc   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source